Pfizer Withdraws Oxbryta Therapy
This is a news story, published by Yahoo, that relates primarily to Oxbryta news.
Oxbryta news
For more Oxbryta news, you can click here:
more Oxbryta newsdrug discoveries news
For more drug discoveries news, you can click here:
more drug discoveries newsYahoo news
For more news from Yahoo, you can click here:
more news from YahooAbout the Otherweb
Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
sickle cell disease therapy Oxbryta. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest Oxbryta news, clinical data news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
Global Blood TherapeuticsReuters
•Pfizer withdraws sickle cell disease treatment from all markets
80% Informative
Pfizer withdraws sickle cell disease therapy Oxbryta in all markets where it is approved.
The company said it does not anticipate that the withdrawal will impact its full-year 2024 financial outlook.
Pfizer acquired the therapy as part of its $5.4 billion buyout of Global Blood Therapeutics in 2022 .
VR Score
90
Informative language
96
Neutral language
62
Article tone
semi-formal
Language
English
Language complexity
57
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
no external sources
Source diversity
no sources
Affiliate links
no affiliate links